HFpEFHeart Failure with Preserved Ejection Fraction
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
"It also highlights the complexity of HFpEF and may suggest some treatments have a more pronounced impact in certain patient groups, including women, who are more likely to suffer from this condition than men."
However, limited data are available regarding the importance of geographical differences in patients with HFpEF Among diverse racial/ethnic groups in different geographical regions, an increase in the number of baseline risk factors is associated with an increased risk of HF (10).
"HFpEF is the single greatest unmet need in cardiology.
EMPEROR-Preserved has randomized 4,126 patients with HFpEF to empagliflozin (Jardiance) or placebo, while EMPEROR-Reduced has 2,850 patients with heart failure with reduced ejection fraction (HFrEF).
Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate: high-dose beta-blocker and outcomes in HFpEF. Am J Med 2018: 1: pii: S0002-9343(18)30731-9.
To date, few clinical trials of Rho kinase inhibitors have been reported in PH associated with left ventricular HFpEF. The goal of this study is to investigate the effects of fasudil on PH-HFpEF and determine the response differences to treatment between RPH and PPH.
Our patient with postoperative pulmonary edema due to HFPEF serves to highlight a gap in preoperative risk stratification.
This drug has been studied in patients with heart failure with both preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).
The patient was diagnosed with heart failure with preserved ejection fraction (HFpEF) due to diastolic dysfunction and high flow state.
It is important to bear in mind that most randomized controlled trials in HF specifically exclude patients with significant comorbidities or HFpEF, yet this group constitutes a significant proportion of older people with HF [3-5].
All of the eligible patients were on guideline-directed medical therapy for either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).